ArticleScientific reports2025
Single-cell transcriptomic analysis reveals distinct cancer-associated fibroblast signatures in treatment-refractory esophageal squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct NK Cell Signatures Define Prognosis in HPV-Positive Versus HPV-Negative Head and Neck Cancer.Cancers · 2026Article
- Research Progress and Future Directions in Immune Cell Crosstalk in the Esophageal Cancer: A Bibliometric Analysis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality worldwide. Despite neoadjuvant concurrent chemoradiotherapy (nCCRT), approximately half of patients exhibit incomplete pathological response with persistent lymph node (LN) infiltration. The tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs) and natural killer (NK) cells, plays crucial roles in treatment outcomes, yet specific cellular signatures associated with LN infiltration status remain poorly characterized. We performed single-cell RNA sequencing analysis on tumor and adjacent normal tissues from 10 ESCC patients who underwent nCCRT followed by surgical resection. Patients were stratified into presence (n = 5) and absence (n = 5) groups based on histological draining LN infiltration status according to ypTNM staging. Cell-type identification, subclustering analysis, differential expression analysis, pathway enrichment, and pseudotime trajectory analysis were performed to characterize infiltration-associated signatures. Analysis of 47,907 cells revealed nine cell populations with significant compositional differences between group. Patients with LN infiltration were characterized by significant enrichment of CLEC2BhimyCAF subtype (10.64% vs. 0.58%), highly expressing NFKB1 and associated with immunosuppressive pathways. Conversely, patients without infiltration showed markedly increased abundance of CD56dim NK subset (19.14% vs. 1.73%), linked to enhanced cytotoxic function. Pseudotime trajectory analysis revealed that cells from different groups occupied opposite ends of trajectories. Treatment-associated cellular signatures extended beyond tumor regions to adjacent normal tissues within the radiation field, indicating regional tissue reprogramming associated with therapeutic exposure. This single-cell analysis reveals that LN infiltration status in ESCC is characterized by distinct TME signatures involving CLEC2BhimyCAF in patients with infiltration and F11RhiCD56dim NK in patients without infiltration. These findings provide new insights into cellular mechanisms underlying different pathological outcomes following nCCRT and offer potential biomarkers for patient stratification and therapeutic targets in ESCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.